Cellebrite Poised to Re-Accelerate in 2026 with Strong Q2 Results

Voss Capital's Q2 2025 investor letter highlights Cellebrite DI Ltd. (NASDAQ:CLBT), a software company that develops solutions for legally sanctioned investigations. Despite a 50% drop from earlier in the year, Cellebrite's Q2 results were "constructive" with revenue guidance cut by 1% and EBITDA guide raised by 2%. ARR was trimmed by 4%, but gross margins remain strong, and free cash flow outpaces EBITDA by 30%. The stock is poised to reaccelerate in 2026 with normalized federal contracts and reaccelerating billings growth.

Voss Capital LP, a prominent hedge fund, has highlighted Cellebrite DI Ltd. (NASDAQ:CLBT) in its Q2 2025 investor letter. Despite a 50% drop in the stock price earlier in the year, the company's Q2 results were described as "constructive" by the fund. Revenue guidance was cut by 1% while EBITDA guidance was raised by 2%. ARR was trimmed by 4%, but gross margins remained strong, and free cash flow outpaced EBITDA by 30% [2].

Cellebrite DI Ltd. is a software company that develops solutions for legally sanctioned investigations. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle. This includes cases such as child exploitation, homicide, anti-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft [1].

Despite the recent stock price drop, the company's performance metrics suggest a potential rebound. The stock is poised to reaccelerate in 2026 with normalized federal contracts and reaccelerating billings growth. The company's CEO, Thomas E. Hogan, was appointed in August 2025, following strong Q2 results [1].

Analysts have maintained a "Buy" rating on the stock, with an average price target of $22.40. Several research analysts have recently issued reports on CLBT shares, including Needham & Company LLC, Lake Street Capital, JPMorgan Chase & Co., and Wall Street Zen. These analysts have set new price targets and maintained their "Buy" ratings [2].

Voss Capital LP has increased its stake in CLBT by 18.6% during the first quarter, making the stock its 9th biggest position. Other institutional investors and hedge funds have also made significant changes to their positions in CLBT, highlighting the stock's potential [2].

In conclusion, while the stock has faced a significant drop in price earlier in the year, the recent performance metrics and analyst ratings suggest that CLBT is poised for a rebound. The company's strong Q2 results and the potential for reacceleration in 2026 make it an attractive investment opportunity for investors.

References:
[1] https://finance.yahoo.com/news/craig-hallum-reiterates-buy-rating-144600553.html
[2] https://www.marketbeat.com/instant-alerts/filing-cellebrite-di-ltd-clbt-shares-purchased-by-voss-capital-lp-2025-08-19/